Investigating how purinergic receptors affect multiple myeloma cells
Official title: Purinergic Receptors in Myeloma
Funded at University of Pennsylvania · NIH-11058658 · Data updated 2026-11-12
This study is looking at how we can target specific receptors in cancer cells to help kill them or stop multiple myeloma from getting worse, using new models that mimic real patients to find better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $621,156 |
| NIH project number | 1R01CA283844-01A1 |
| Project ID | NIH-11058658 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple myeloma or those with premalignant plasma cell conditions.
✕Less likely to help
Patients with other types of blood cancers or those not diagnosed with plasma cell disorders may not benefit from this research.
What this research studies
This research focuses on understanding how certain receptors in malignant plasma cells can be targeted to induce their death or prevent the progression of multiple myeloma, a serious blood cancer. The study aims to explore the role of extracellular ATP and specific receptors in the survival of these cancer cells within the bone marrow. By using innovative models, including patient-derived xenografts, the research will investigate the mechanisms that allow myeloma cells to evade death and how disrupting these signals could lead to new treatment options.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that more effectively eliminate multiple myeloma cells and reduce the risk of relapse.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Allman, David M — University of Pennsylvania
- Study coordinator: Allman, David M
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.